Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
As a result of the changing landscape in dermatological care and increased awareness about keloid disorders, there have been trends in the Keloid Treatment Market. This market specializes in providing remedies for treating or managing keloids, which are raised overgrowths of scar tissue that can develop at the site of a healed skin injury. Among other things, one notable trend within the Keloid Treatment Market is an increasing prevalence of keloids, along with greater awareness of their impact on patients' lives. Individuals who may be genetically predisposed tend to bear most brunt disproportionate to other sufferers due to various forms of skin injuries like surgical wounds, burns, or even minor cuts. Wider knowledge among medical practitioners as well as the general masses about all these conditions has led to early diagnosis, hence an increase in the need for effective therapy options, resulting in increased demand for better therapeutic remedies. This trend is projected to push towards overall growth within the Keloid Treatment Market.
Additionally, technological improvements and innovations regarding modalities used in treatments have played a part in shaping this industry environment. These therapies include corticosteroid injections and surgical excisions, which are accompanied by other newer alternatives recently introduced into this field. Likewise, other methods, such as laser therapy, cryotherapy, and radiotherapy, are increasingly becoming popular among patients and healthcare providers as alternative treatment options. Furthermore, there is a shift towards combination therapies and multidisciplinary approaches in the Keloid Treatment Market. This means that doctors are realizing that keloid management will require a comprehensive approach that utilizes diverse treatment modalities. These days, a number of combination treatments are available to clinicians who may choose between, for example, post-surgical radiation therapy or intra-lesional injections with lasers added on. With regards to keloids, this trend can be linked to the notion of an all-around therapeutic approach that tackles different aspects of the disease, leading to better outcomes.
The last notable trend in the Keloid Treatment Market is patient-centric care. The field of keloid treatments has adjusted itself in order to meet these expectations since personalized medicine has become highly relevant. Improved treatments for keloids have been made possible through collaborations and partnerships with healthcare organizations, research institutions, and pharmaceutical companies. Such entities collaborate in various ways, including carrying out research and development activities that lead to new therapeutic discoveries. However, there remain challenges bedeviling the market for Keloids Treatment today despite these advancements. The persistent lack of awareness in some areas, disparities in treatment outcomes, and chances of reoccurrence keep on haunting them. Additionally, providing advanced therapies at affordable prices is still a challenge, especially due to availability issues facing developing countries.
Keloid Treatment Market Highlights:
Global Keloid Treatment Market Overview
The keloid treatment market is expected to reach USD 1.72 Billion by 2032 and is expected to increase at a CAGR of 3.3% during the forecast period 2023-2032. A keloid is a thickened scar that rises over the surrounding skin. It is usually pink or purple. Keloids are unevenly shaped scars that appear on the skin and grow in size over time.
Keloids, unlike other scars, do not fade over time. According to the National Library of Medicine in the United States, keloid scarring affects people of all ages, although dark-skinned persons are more susceptible, with between 6% to 16% of African populations suffering from keloid skin disorders. Due to significant advancements in technology skincare products, the keloid treatment industry is likely to increase. The market is also rising as individuals become more aware of the various treatment methods and other items available to cure keloid. Additionally, increased spending on skincare products and services, as well as changing lifestyles, have all contributed to the Keloid Treatment Market's growth. However, the market is being driven by increasing awareness among patients, particularly females, about their looks. Clinics and hospitals are focused on the adoption of modern therapy alternatives as the demand for keloid treatment grows. Sensus Healthcare recently developed a superficial radiation therapy device to give better treatment with fewer side effects.
POETYK PSO-2, the second pivotal Phase III clinical trial assessing deucravacitinib, a new, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis, was published in February 2021 by Bristol Myers Squibb Company. POETYK PSO-2 looked at deucravacitinib 6 mg once a day and found that it met both co-primary objectives, with considerably more patients reaching Psoriasis Area and Severity Index (PASI 75). JUBLIA (efinaconazole) topical solution for the treatment of onychomycosis was approved by the US Food and Drug Administration (FDA) in April 2020 for Bausch Health Companies Inc. and its dermatology business Ortho Dermatologics in Keloid Treatment Market
The market for keloid treatment is expected to grow as a result of major innovations in skincare products' technology. As more people learn about the many options for curing keloids, the industry expands to accommodate them. The Keloid Treatment Market has expanded due to a number of factors, including the rising demand for skincare goods and services and the shift toward more health-conscious lifestyles. However, the business is being driven by patients' growing consciousness of their appearance, especially among women. As more people seek help for keloids, medical facilities are increasingly looking to cutting-edge therapy options.
In addition to technological progress and rising knowledge of the availability of aesthetic surgery, an increase in the frequency of road accidents and burn cases has been a major factor promoting the industry's adoption throughout the years. The rising rate of both car accidents and burns around the world is expected to fuel growth in the keloid treatment industry. It is anticipated that technical development will further increase the company's profit margin. Laser therapies are becoming increasingly popular for the treatment and removal of scars. In addition, numerous businesses have recently unveiled cutting-edge laser therapy scar solutions.
In January 2023, Sonoma Pharmaceuticals, Inc., a global leader in the development and production of stabilized hypochlorous acid (HOCl) products for a variety of applications, including dermatology, eye, oral, and nasal care, and wound care, announced the launch of a line of office dispense products designed specifically for skin care professionals. The medications are in prescription strength and include Regenacyn® Plus, Reliefacyn® Plus, and Rejuvacyn® Plus. Regenacyn Plus has been shown in clinical trials to reduce itching and pain associated with keloid and hypertrophic scars, as well as enhance the appearance, texture, and color of the scars itself.
Aesthetic professionals and patients can visualize injectable treatment results when planning through the use of FACE by Galderma™, a new aesthetic visualization tool based on augmented reality (AR), launched today by Galderma in March 2023. This will allow a patient to envision whether or not they want to go ahead with an injection. An individualized treatment plan might offer simulated real-time before and after photos, which would help allay anxiety about injectables. Thus, through FACE by Galderma, there can be an immersive interactive consultation between the provider and the patient. It is designed for aesthetic practitioners and evaluates skin quality, face shape, proportion, contouring symmetry, and facial expressions expressed through animations.
In February 2022, Merz Aesthetics announced its commercial release of Radiesse® (+) Lidocaine soft tissue filler for deep injection under the skin (subdermal) or above the periosteum (supraperiosteal) in adult patients aged over twenty-one years to correct moderate-to-severe loss of jawline volume. Radiesse Injectables constitute the very first and only calcium hydroxylapatite (CaHA) portfolio in America, whereas Radiesse (+) is currently the single FDA-approved injectable treatment for improving jawline contours. In September 2021, the Food and Drug Administration approved an additional Premarket Approval Application.
Sonoma Pharmaceuticals has just released a line of office dispense products that are exclusively available to skincare specialists; this was made known on January 2023 by Sonoma Pharmaceuticals, Inc., a global healthcare leader that uses patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for various applications such as dermatology, eye care, oral care/healthcare nasal care, wound care among others. The prescription-strength formulations include Regenacyn® Plus, Reliefacyn ®Plus, and Rejuvacyn® Plus. Dermatology practices and medical spas will be the target for Sonoma’s distribution program in-office. Consequently, instead of going to a pharmacy, clients can buy prescription strength products directly from their skin care professional.
Keloid Treatment Market Segment Insights
The keloid treatment market is segmented into product type, treatment, and end-users.
Keloid Treatment Product Type Insights
Based on product type the market is segmented into elastic wraps, spray, ointment, creams, oils, topical gels & gel sheets.
Keloid Treatment Insights
Based on treatment market for keloid has been segmented into ligature, radiation therapy, cry therapy, surgical treatment, laser treatment, steroid injections, corticosteroid injections (intralesional steroids), silicone gel or sheeting, occlusive dressing, compression therapy, and interferon. Corticosteroid injections treatment segments lead the keloid treatment market as this treatment is used in combination with other therapies. Intralesional steroids injection is considered to be the second largest segment of treatment type that drives market.
Keloid Treatment End-User Insights
On the basis of end-users, the keloid treatment market is segmented into dermatology clinics, hospitals, ambulatory surgical centers. Hospital is expected to hold the largest share in the segment market of end-users as most doctors prefer radiation therapy which has reported safe and effective use of radiation to treat keloid.
Keloid Treatment Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European keloid treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
In January 2023, The results of a new in-depth examination of data from the UK Biobank into the impact of co-morbidities on disfigurement from keloid and hypertrophic scars (excessive scarring) indicate the need for more research into the pathophysiology of excessive scarring. Atopic eczema in particular was linked to an increased risk of scarring. Keloid scars and hypertrophic scars both result from skin wounds, however keloid scars are permanent whereas hypertrophic scars may fade with time. Candidate disorders based on hypothesized biological or demographic similarities have been the focus of prior research into the co-occurrence of keloids and hypertrophic scars.
Regional Market Summary
Geographically, North America dominates the keloid treatment market and is expected to continue to dominate the market throughout the forecast period. Clinics in North America are adopting advanced technologies for the treatment of keloid. Development of new technologies, product, alternative treatment and high disposable income of people in this region is responsible for the rapid growth of the keloid treatment market in this region.
Europe is the second largest market in the globe owing to the increasing awareness among people, favorable reimbursement scenario for skin treatment, increasing government expenditure for skin care product, the presence of disposable income and increasing demand for the cosmetic product.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of skin caries, increased focus on appearance and aesthetic in the developing countries, rising population, increasing disposable income, and growing healthcare expenditure are anticipated to increase the keloid treatment market in Asia-Pacific.
The Middle East & Africa is expected to account for the lowest market share in the keloid treatment market due to low development, lack of technical knowledge, and poor medical facilities in developing economies in this region.
Global Keloid Treatment Market Share (%), by Region, 2017 
Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American College of Prosthodontists
Key players:
Some of the key players in the keloid treatment market are
- Novartis AG
- RXi Pharmaceuticals, Inc.
- Sonoma Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Pacific World Corporation
- Valeant Pharmaceuticals International, Inc.
- Revitol Corporation
- Avita Medical Limited
- Sensus Healthcare
- Perrigo Company plc.
Keloid Treatment Market Segmentation
Keloid Treatment Product Type Outlook
- Elastic Wraps
- Sprays
- Ointment
- Creams
- Oils
- Topical Gels & Gel Sheets
Keloid Treatment Treatment Outlook
- Ligature
- Radiation Therapy
- Cry Therapy
- Surgical Treatment
- Laser Treatment
- Steroid Injections
- Corticosteroid injections (intralesional steroids)
- Silicone gel or sheeting
- Interferon
Keloid Treatment End User Outlook
- Dermatology clinics
- Hospitals
- Ambulatory surgical centers
- Others
Keloid Treatment Region Outlook
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- Middle East & Africa
- Middle East
- Africa
Recent Development
POETYK PSO-2, the second pivotal Phase III clinical trial assessing deucravacitinib, a new, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis, was published in February 2021 by Bristol Myers Squibb Company. POETYK PSO-2 looked at deucravacitinib 6 mg once a day and found that it met both co-primary objectives, with considerably more patients reaching Psoriasis Area and Severity Index (PASI 75). JUBLIA (efinaconazole) topical solution for the treatment of onychomycosis was approved by the US Food and Drug Administration (FDA) in April 2020 for Bausch Health Companies Inc. and its dermatology business Ortho Dermatologics in Keloid Treatment Market
Intended Audience
- Manufacturers and Suppliers
- Dermatology Hospitals and Clinics
- Dermatology laboratories and associations
- Research and development centers
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
